These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25652638)

  • 1. The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy.
    Zhang GM; Zhu Y; Dong DH; Han CT; Gu CY; Gu WJ; Qin XJ; Sun LJ; Ye DW
    Asian J Androl; 2015; 17(5):839-44. PubMed ID: 25652638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
    De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
    BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between metabolic syndrome and prostate cancer: Effect on its aggressiveness and progression.
    Sanchís-Bonet A; Ortiz-Vico F; Morales-Palacios N; Sánchez-Chapado M
    Actas Urol Esp; 2015 Apr; 39(3):154-60. PubMed ID: 25454266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
    Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
    Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
    Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
    Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
    Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
    Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
    Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
    Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
    Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
    Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between prostate cancer and presence of metabolic syndrome and late-onset hypogonadism.
    Kayali M; Balci M; Aslan Y; Bilgin O; Guzel O; Tuncel A; Atan A
    Urology; 2014 Dec; 84(6):1448-52. PubMed ID: 25281522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
    De Nunzio C; Brassetti A; Simone G; Lombardo R; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):438-445. PubMed ID: 29867154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy.
    Shiota M; Yokomizo A; Takeuchi A; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    J Surg Oncol; 2014 Sep; 110(4):476-81. PubMed ID: 24898352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of metabolic syndrome and prostate cancer.
    Gacci M; Russo GI; De Nunzio C; Sebastianelli A; Salvi M; Vignozzi L; Tubaro A; Morgia G; Serni S
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):146-155. PubMed ID: 28220805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
    Ellis CL; Partin AW; Han M; Epstein JI
    J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robotic-assisted laparoscopic prostatectomy in men with metabolic syndrome.
    Kwon YS; Leapman M; McBride RB; Hobbs AR; Collingwood SA; Stensland KD; Samadi DB
    Urol Oncol; 2014 Jan; 32(1):40.e9-16. PubMed ID: 23820091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens.
    Kryvenko ON; Gupta NS; Virani N; Schultz D; Gomez J; Amin A; Lane Z; Epstein JI
    Arch Pathol Lab Med; 2013 May; 137(5):610-7. PubMed ID: 23627451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidental prostate cancer in Asian men: high prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy.
    Yang X; Monn MF; Liu L; Liu Y; Su J; Lyu T; Gong Y; Wang L; Davidson DD; Cheng L
    Prostate; 2015 Jun; 75(8):845-54. PubMed ID: 25704311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy.
    Pettus JA; Al-Ahmadie H; Barocas DA; Koppie TM; Herr H; Donat SM; Dalbagni G; Reuter VE; Olgac S; Bochner BH
    Eur Urol; 2008 Feb; 53(2):370-5. PubMed ID: 17689003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study.
    Cicione A; De Nunzio C; Tubaro A; Cantiello F; Manno S; Oliveira C; Lima E; Damiano R
    BMC Cancer; 2016 Feb; 16():59. PubMed ID: 26846521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.